![Albert Paszek](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Albert Paszek
Former positions of Albert Paszek
Companies | Position | Start | End |
---|---|---|---|
MUSTANG BIO, INC. | Chief Tech/Sci/R&D Officer | 01/10/2019 | 10/10/2023 |
ALEXION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/02/2016 | 01/08/2017 |
SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | - | - |
ABEONA THERAPEUTICS INC. | Corporate Officer/Principal | - | - |
Training of Albert Paszek
University of Minnesota | Doctorate Degree |
Statistics
International
United States | 6 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
MUSTANG BIO, INC. | Health Technology |
ABEONA THERAPEUTICS INC. | Health Technology |
Private companies | 2 |
---|---|
Alexion Pharmaceuticals, Inc.
![]() Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Synageva BioPharma Corp.
![]() Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
- Stock Market
- Insiders
- Albert Paszek
- Experience